文献
J-GLOBAL ID:201702216393298233
整理番号:17A1446722
健常人における慢性B型肝炎ウイルス感染の治療のためのRNA干渉に基づく治療,アーク520投与の安全性,忍容性,および薬物動態【Powered by NICT】
Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers
著者 (9件):
Schluep Thomas
(Arrowhead Pharmaceuticals, Inc., Pasadena, CA, USA)
,
Lickliter Jason
(Nucleus Network, Melbourne, Australia)
,
Hamilton James
(Arrowhead Pharmaceuticals, Inc., Pasadena, CA, USA)
,
Lewis David L.
(Arrowhead Pharmaceuticals, Inc., Pasadena, CA, USA)
,
Lai Ching-Lung
(The University of Hong Kong, Hong Kong, China)
,
Lau Johnson YN
(The Hong Kong Polytechnic University, Hong Kong, China)
,
Locarnini Stephen A.
(Victorian Infectious Diseases Reference Laboratory, Victoria, Australia)
,
Gish Robert G.
(Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Stanford, CA, USA)
,
Given Bruce D.
(Arrowhead Pharmaceuticals, Inc., Pasadena, CA, USA)
資料名:
Clinical Pharmacology in Drug Development
(Clinical Pharmacology in Drug Development)
巻:
6
号:
4
ページ:
350-362
発行年:
2017年
JST資料番号:
W2780A
ISSN:
2160-7648
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)